Earlier today, the FDA approved mepolizumab (Nucala; GSK) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The approval was supported in part by findings from the phase 3 […]
Gerard Criner, MD, FACP, FACCP Read More »
Evernorth, Cigna’s health services division, secured a $200 monthly co-pay cap for the antiobesity medications semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly) through direct negotiations with manufacturers.1 The move comes as federal efforts to reduce prescription drug costs
Evernorth Launches Co-Pay Cap for Weight Loss Drugs Amid New Federal Drug Pricing Effort Read More »
The FDA approved mepolizumab (Nucala; GSK) today as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.1 Mepolizumab is a monoclonal antibody that targets IL-5, a cytokine with a central
Paying Medicare Advantage (MA) plans current annual capitated rates to cover veterans whose care is primarily paid for by the Department of Veterans Affairs (VA) may not be fully justified by supplemental vision and dental care benefits, as related visits
Supplemental Dental, Vision Benefits May Not Justify MA Payments for VA-Covered Veterans Read More »
In the final part of her interview with The American Journal of Managed Care®, Emma Achola-Kothari, PhD, lead investigator of “Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years,” a study published in the May 2025 issue, discusses
In part 2 of an interview with Margrit Wiesendanger, MD, PhD, of the Icahn School of Medicine at Mount Sinai, she discusses the most commonly used treatments for lupus and how the landscape is evolving with innovations like biologics. She
Emma Achola-Kotari, PhD, continues her conversation with The American Journal of Managed Care®, expanding on findings from her study, “Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years,” published in the May 2025 issue, with a focus on
In part 1 of an interview with Emma Achola-Kothari, PhD, lead investigator of “Evaluating Access to Care for Medicare Beneficiaries Younger Than 65 Years,” a study published in the May 2025 issue of The American Journal of Managed Care®, she
In part 1 of an interview with The American Journal of Managed Care®, Margrit Wiesendanger, MD, PhD, provides an overview of lupus, including its clinical presentation, diagnostic challenges, and the populations most affected by the disease. Wiesendanger is a clinical
Significant facility-level disparities exist in the adoption of minimally invasive interval debulking surgery among patients with advanced epithelial ovarian cancer, and these gaps may widen if no action is taken as the procedure becomes more commonly utilized.1 The authors of
